Browse Health


Education ?

Medical School Score
Loma Linda University (1973)

Awards & Distinctions ?

American Board of Pediatrics

Affiliations ?

Dr. Turnbow is affiliated with 5 hospitals.

Hospital Affiliations



  • Covenant Medical Center
    3615 19th St, Lubbock, TX 79410
    Top 25%
  • University Medical Center - Lubbock
    602 Indiana Ave, Lubbock, TX 79415
  • Covenant Children's Hospital
    3610 21st St, Lubbock, TX 79410
  • Univ Medical Center Ttuhsc
  • University Medical Center
  • Publications & Research

    Dr. Turnbow has contributed to 5 publications.
    Title Long-term Tolerability of the Methylphenidate Transdermal System in Pediatric Attention-deficit/hyperactivity Disorder: a Multicenter, Prospective, 12-month, Open-label, Uncontrolled, Phase Iii Extension of Four Clinical Trials.
    Date December 2009
    Journal Clinical Therapeutics

    Short-term treatment with the meth-ylphenidate transdermal system (MTS) has been well tolerated in several clinical trials in children with attention-deficit/hyperactivity disorder (ADHD). However, the effects of long-term use have not been systematically evaluated.

    Title Varying the Wear Time of the Methylphenidate Transdermal System in Children with Attention-deficit/hyperactivity Disorder.
    Date June 2008
    Journal Journal of the American Academy of Child and Adolescent Psychiatry

    OBJECTIVE: Children with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD. METHOD: Methylphenidate dose was optimized over 5 weeks using 10-, 15-, 20-, or 30-mg patches worn for 9 hours. The efficacy of 4- and 6-hour wear times was then assessed in an Analog Classroom setting during a randomized, placebo-controlled, double-blind, three-way crossover phase. The main efficacy measures were the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale deportment scale and the Permanent Product Measure of Performance math test. RESULTS: All of the efficacy measures indicated that 4- and 6-hour wear times improved ADHD symptoms and that medication effects on the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale deportment scale and Permanent Product Measure of Performance math test decreased between 2 and 4 hours after patch removal. The majority of adverse events were transient and mild to moderate in severity. CONCLUSIONS: These findings suggest that the duration of medication effect is related to the wear time of the patch and may be tailored to accommodate the schedules of patients.

    Title A Randomized, Double-blind, Placebo-controlled, Laboratory Classroom Assessment of Methylphenidate Transdermal System in Children with Adhd.
    Date June 2006
    Journal Journal of Attention Disorders

    OBJECTIVE: This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system (MTS) in children with ADHD. METHOD: Participants were dose optimized over 5 weeks utilizing patch doses of 10, 16, 20, and 27 mg applied in the morning and worn for 9 hours. Following optimization, 80 participants were randomized to 1 week of MTS or placebo followed by 1 week of the opposite treatment. Laboratory classroom sessions conducted after each randomized week included blinded ratings of attention, behavior, and academic performance. RESULTS: MTS was well tolerated and displayed significant improvement compared with placebo. Improvements were seen at the first postdose time point measured and continued through 12 hours. CONCLUSIONS: Treatment with MTS resulted in statistically significant improvements on all efficacy measures. Time course and therapeutic effects of MTS suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD.

    Title Discrepancy Standard.
    Date May 1991
    Journal Journal of Learning Disabilities
    Title Intestinal Absorption and Biliary Excretion Kinetics of 14c-labeled Methadone in the Rat.
    Date October 1976
    Journal Archives Internationales De Pharmacodynamie Et De Thérapie

    Intestinal abosrption, biliary excretion and enterohepatic circulation of d,l-methadone were studied in male, female, fasted and fed rats by monitoring the appearance of radioactivity in the portal vein, the inferior vena cava, and the bile following intraduodenal administration of 2-14C-d,l-methadone. An early peak in portal concentration was not reflected in the peripheral blood or in the bile. An enterohepatic circulation exists, but is minimal, accounting for less than 1% of the dose in the first hr. Experimental diversion of the bile flow from the lumen of the duodenum has little effect on the relative percentage of methadone vs. metabolites circulating in the blood. However, bile diversion was associated with a 2 to 3 fold increase in the concentration of methadone and its metabolites in portal and peripheral blood 30 min following administration. Eighty to 90% of the 14C in the portal blood is present as methadone and 60 to 70% of the 14C in peripheral blood is methadone while less than 10% of the radioactive materials in the bile is methadone. The amount of metabolite No. 1, metabolite No. 2 and water soluble metabolites vary with over 60% of the radioactive compounds in recirculated bile in the form of water soluble materials.

    Similar doctors nearby

    Dr. Amanda Masters

    7 years experience
    Lubbock, TX

    Dr. Michal Pankratz

    Lubbock, TX

    Dr. Noel Ellis

    Lubbock, TX

    Dr. Joon Park

    Lubbock, TX

    Dr. Stacy Clinton

    4 years experience
    Lubbock, TX

    Dr. Douglas Klepper

    23 years experience
    Lubbock, TX
    Search All Similar Doctors